Aspen Aerogels (ASPN) Misses Q3 EPS by 11c, Beats on Revenue; Offers FY24 Revenue Guidance

Aspen Aerogels (NYSE: ASPN) reported Q3 EPS of ($0.17), $0.11 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $117.3 million versus the consensus estimate of $107.85 million.

GUIDANCE:

Aspen Aerogels sees FY2024 revenue of $450 million, versus the consensus of $415.2 million.

For earnings history and earnings-related data on Aspen Aerogels (ASPN) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'
• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO